Moderate

Non-tuberculous mycobacterial pulmonary disease

NTM lung · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

NTM pulmonary disease (commonly Mycobacterium avium complex or M. abscessus) causes chronic cough, bronchiectasis and nodular/cavitary disease, especially in older women and those with structural lung disease. Diagnosis requires clinical, radiological and microbiological criteria; treatment is prolonged multidrug therapy.

Red flags

  • Haemoptysis or massive haemoptysis
  • Progressive cavitation and weight loss
  • Macrolide resistance on susceptibility testing
  • Rapid clinical deterioration suggesting disseminated/immunodeficient disease

Assessment

Differential diagnosis

  • Tuberculosis
  • Bronchiectasis from other cause
  • Aspergillosis
  • Lung cancer
  • Chronic bacterial bronchial infection

Investigations

  • HRCT chest (nodular bronchiectasis, tree-in-bud, cavitation)
  • At least two separate sputum cultures positive for the same NTM species (or one positive BAL/biopsy)
  • Species identification and drug-susceptibility testing (macrolide, amikacin)
  • Exclude/treat TB and other pathogens
  • Spirometry and weight/nutrition assessment
  • Screen for predisposing conditions (CF, alpha-1 antitrypsin, immunodeficiency, GORD)

Management

  • Confirm NTM disease using ATS/ERS/IDSA clinical, radiological and microbiological criteria (not colonisation)
  • Identify species and obtain susceptibility, especially macrolide and amikacin
  • Assess disease severity: nodular-bronchiectatic vs fibrocavitary and symptom burden
  • Decide whether to treat or observe — not all disease needs immediate therapy
  • For MAC, start guideline multidrug therapy with a macrolide-ethambutol-rifamycin backbone
  • Add or switch to IV/inhaled amikacin for cavitary, severe or refractory disease
  • Treat M. abscessus with an initial intensive IV phase then a prolonged continuation regimen
  • Continue therapy until culture-negative for at least 12 months
  • Optimise airway clearance, nutrition and comorbidities; treat concurrent bronchiectasis
  • Monitor for drug toxicity (vision, hearing, renal, hepatic) and consider surgery for localised refractory disease

Drugs & doses

Azithromycin 250-500 mg PO once daily (or 500 mg three times weekly) — macrolide backbone
Ethambutol 15 mg/kg PO once daily
Rifampicin 600 mg PO once daily (rifabutin alternative)
Amikacin liposomal inhalation 590 mg nebulised once daily for refractory MAC; or IV amikacin 15 mg/kg for severe disease
M. abscessus: IV amikacin + imipenem or cefoxitin + oral macrolide (if susceptible) induction

Disposition

Specialist respiratory / mycobacterial clinic; long-term monitored multidrug therapy; thoracic surgery for localised refractory disease.

Complications & pitfalls

  • Chronic respiratory failure and progressive bronchiectasis
  • Drug toxicity (ocular, ototoxicity, hepatotoxicity, renal)
  • Macrolide-resistant treatment failure
  • Massive haemoptysis / aspergilloma in cavities

Exam pearls

  • Never use a macrolide as monotherapy — it breeds resistance; always combine
  • Isolating NTM once often reflects colonisation; diagnosis needs repeated positives plus disease
  • M. abscessus is notoriously hard to cure and often requires surgery
  • Classic 'Lady Windermere' phenotype: slim older woman with lingula/middle-lobe nodular bronchiectasis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.